Technology evaluation: Denosumab, Amgen

Bo Abrahamsen; Andy Y.T. Teng

Technology evaluation: Denosumab, Amgen

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Review › Forskning › peer review

Abstract

Amgen, as part of it's program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-κ B ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

Originalsprog	Engelsk
Sider (fra-til)	604-610
Antal sider	7
Tidsskrift	Current Opinion in Molecular Therapeutics
Vol/bind	7
Udgave nummer	6
Status	Udgivet - 1 dec. 2005

Andre filer og links

https://www.scopus.com/pages/publications/28844502782

Citationsformater

@article{bdcdd66573d64f99b06acce66937e501,

title = "Technology evaluation: Denosumab, Amgen",

abstract = "Amgen, as part of it's program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-κ B ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.",

author = "Bo Abrahamsen and Teng, \{Andy Y.T.\}",

year = "2005",

month = dec,

day = "1",

language = "English",

volume = "7",

pages = "604--610",

journal = "Current Opinion in Molecular Therapeutics",

issn = "1464-8431",

publisher = "Current Drugs Ltd.",

number = "6",

}

TY - JOUR

T1 - Technology evaluation

T2 - Denosumab, Amgen

AU - Abrahamsen, Bo

AU - Teng, Andy Y.T.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Amgen, as part of it's program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-κ B ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

AB - Amgen, as part of it's program targeting the RANK/RANKL/ osteoprotegerin pathway, is developing denosumab, a fully human monoclonal antibody, delivered subcutaneously, targeting the receptor activator of nuclear factor-κ B ligand, for the potential treatment of diseases associated with bone loss, such as osteoporosis and bone metastases. The antibody is currently undergoing phase III clinical trials.

UR - https://www.scopus.com/pages/publications/28844502782

M3 - Review

C2 - 16370384

AN - SCOPUS:28844502782

SN - 1464-8431

VL - 7

SP - 604

EP - 610

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

IS - 6

ER -

Technology evaluation: Denosumab, Amgen

Abstract

Andre filer og links

Fingeraftryk

Citationsformater